Pamela J. McLean

This study identifies miRNA biomarkers in brain-derived extracellular vesicles from plasma to distinguish Lewy body disease from Alzheimer's disease with high accuracy.

This study examines the distribution of α-synuclein oligomers in LRRK2-related Parkinson's disease, finding a negative correlation between oligomers and Lewy-related pathology.

This study shows honokiol reduces alpha-synuclein mRNA and protein levels in models of Parkinson's disease by modulating SNCA gene expression, identifying potential therapeutic targets.

This study shows that alpha-synuclein oligomers reduce mitochondrial SIRT3 activity, impair mitochondrial dynamics, and that AICAR treatment restores SIRT3 and improves mitochondrial dysfunction in Parkinson's disease models.

This paper introduces a CRISPR/Cas9 strategy to edit APP and manipulate the amyloid pathway in Alzheimer's disease by reducing β-cleavage and Aβ while increasing α-cleavage.